The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday. This update wasn't well-received by investors, and Moderna's share price ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

its only commercially available product until its RSV shot entered the market last year. It also comes ahead of Moderna's presentation at the annual JPMorgan Healthcare Conference, one of the largest ...

Companies that bring products to market quickly and efficiently are better positioned to succeed and improve patient outcomes. Or so the industry wisdom goes. The go-to-market feat of Moderna ...

Rather than spending to explore new products ... that key risks specific to Moderna include the "potential for greater-than-anticipated drop-off in the COVID market, possible failure to show ...